VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.
The agreement gives EUCODIS Bioscience exclusive access - for the search of enzymes of interest - to Bio Sidus' proprietary collection of psychrophilic bacteria strains and other organisms isolated from the Antarctic and the surrounding oceans. Psychrophiles are organisms that thrive at low temperatures. EUCODIS Bioscience will use its experience in enzyme development to screen the strains for enzymatic activities that can be used in industrial and other commercial applications.
"We are excited that EUCODIS Bioscience gains access to Bio Sidus' collection of psychrophilic microorganisms with their wealth of hitherto untapped biological diversity," commented Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience.
"The biological diversity of organisms that are adapted to an extremely cold environment offers a huge potential for the discovery and development of novel enzymes. Enzymes that enable or accelerate chemical processes at a low temperature offer tremendous commercial and environmental advantages for energy-intensive industrial processes as well as for detergents and other products for domestic applications."
About EUCODIS Bioscience
EUCODIS Bioscience GmbH develops, optimizes, manufactures, and markets industrial enzymes.
EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.
EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.
Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.
For more information, please visit http://www.eucodisbioscience.com
About Bio Sidus
Bio Sidus is the leading biopharmaceutical company in Latin America. Bio Sidus currently manufactures and markets human erythropoietin, human growth hormone and human interferon Alfa 2a and 2b, amongst other proprietary biotech developments. The company is part of Grupo Sidus, a leading developer and manufacturer and pharmaceuticals, active pharmaceutical ingredients (APIs) and biopharmaceuticals that are marketed in more than 90 countries. Bio Sidus is based in Buenos Aires, Argentina, and has 250 employees.
CONTACT: Company contact EUCODIS Bioscience: Rudy Pandjaitan, PhD, CEO,
EUCODIS Bioscience, Campus Vienna Biocenter II, Viehmarktgasse 2 a/ 2 OG,
A-1030 Vienna, AUSTRIA, +43-1-8900804, email@example.com. Media
contact EUCODIS Bioscience: Frank Butschbacher, Investor Relations &
Communications, http://www.butschbacher.net, +43-650-7844940,